Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 25 Jun 2020 |
| Orion Corporation has decided on cancellation of shares on the joint account | 15 Jun 2020 |
| Orion Corporation: Managers’ transactions – Mikael Silvennoinen | 12 Jun 2020 |
| Orion Corporation: Managers’ transactions – Lehtoranta, Ari | 12 Jun 2020 |
| Orion Corporation: Managers’ transactions – Eija Ronkainen | 12 Jun 2020 |